Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marco Miceli is active.

Publication


Featured researches published by Marco Miceli.


Journal of Medicinal Chemistry | 2008

epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors.

Antonello Mai; Donghang Cheng; Mark T. Bedford; Sergio Valente; Angela Nebbioso; Andrea Perrone; Gerald Brosch; Gianluca Sbardella; Floriana De Bellis; Marco Miceli; Lucia Altucci

A number of new compounds bearing two ortho-bromo- and ortho, ortho-dibromophenol moieties linked through a saturated/unsaturated, linear/(poly)cyclic spacer (compounds 1- 9) were prepared as simplified analogues of AMI-5 (eosin), a recently reported inhibitor of both protein arginine and histone lysine methyltransferases (PRMTs and HKMTs). Such compounds were tested against a panel of PRMTs (RmtA, PRMT1, and CARM1) and against human SET7 (a HKMT), using histone and nonhistone proteins as a substrate. They were also screened against HAT and SIRTs, because they are structurally related to some HAT and/or SIRT modulators. From the inhibitory data, some of tested compounds ( 1b, 1c, 4b, 4f, 4j, 4l, 7b, and 7f) were able to inhibit PRMTs, HKMT, HAT, and SIRTs with similar potency, thus behaving as multiple ligands for these epigenetic targets (epi-MLs). When tested on the human leukemia U937 cell line, the epi-MLs induced high apoptosis levels [i.e., 40.7% ( 4l) and 42.6% ( 7b)] and/or massive, dose-dependent cytodifferentiation [i.e., 95.2% ( 1c) and 96.1% ( 4j)], whereas the single-target inhibitors eosin, curcumin, and sirtinol were ineffective or showed a weak effect.


EMBO Reports | 2009

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes

Angela Nebbioso; Fabio Manzo; Marco Miceli; Mariarosaria Conte; Lucrezia Manente; Alfonso Baldi; Antonio De Luca; Dante Rotili; Sergio Valente; Antonello Mai; Alessandro Usiello; Hinrich Gronemeyer; Lucia Altucci

Histone deacetylase (HDAC) inhibitors are promising new epi‐drugs, but the presence of both class I and class II enzymes in HDAC complexes precludes a detailed elucidation of the individual HDAC functions. By using the class II‐specific HDAC inhibitor MC1568, we separated class I‐ and class II‐dependent effects and defined the roles of class II enzymes in muscle differentiation in cultured cells and in vivo. MC1568 arrests myogenesis by (i) decreasing myocyte enhancer factor 2D (MEF2D) expression, (ii) by stabilizing the HDAC4–HDAC3–MEF2D complex, and (iii) paradoxically, by inhibiting differentiation‐induced MEF2D acetylation. In vivo MC1568 shows an apparent tissue‐selective HDAC inhibition. In skeletal muscle and heart, MC1568 inhibits the activity of HDAC4 and HDAC5 without affecting HDAC3 activity, thereby leaving MEF2–HDAC complexes in a repressed state. Our results suggest that HDAC class II‐selective inhibitors might have a therapeutic potential for the treatment of muscle and heart diseases.


Bioorganic & Medicinal Chemistry Letters | 2008

Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases

Gianluca Sbardella; Sabrina Castellano; Caterina Vicidomini; Dante Rotili; Angela Nebbioso; Marco Miceli; Lucia Altucci; Antonello Mai

Pentadecylidenemalonate 1b, a simplified analogue of anacardic acid, was identified as the first mixed activator/inhibitor of histone acetyltransferases (HATs). It potentiates PCAF HAT activity while inhibiting those of p300/CBP and recombinant CBP. The remarkable apoptotic effect together with the ability to selectively acetylate histone versus non-histone substrates appoint 1b as a lead for the development of anticancer drugs.


Molecular Cancer Therapeutics | 2011

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008

Angela Nebbioso; Raquel Pereira; Harshal Khanwalkar; F. Matarese; J. García-Rodríguez; Marco Miceli; C. Logie; V. Kedinger; Felicetto Ferrara; H.G. Stunnenberg; A.R. de Lera; Hinrich Gronemeyer; Lucia Altucci

Deregulation of the epigenome is recognized as cause of cancer and epigenetic factors are receiving major attention as therapeutic targets; yet, the molecular mode of action of existing epi-drugs is largely elusive. Here, we report on the decryption of the mechanism of action of UVI5008, a novel epigenetic modifier, that inhibits histone deacetylases, sirtuins, and DNA methyltransferases. UVI5008 highly efficiently induces cancer cell–selective death in a variety of models and exerts its activities in several human tumor xenografts and genetic mouse models of human breast cancer in vivo. Its anticancer activity involves independent activation of death receptors and reactive oxygen species production. Importantly, UVI5008 action is not critically dependent on p53, Bcl-2 modifying factor, and/or TNF-related apoptosis-inducing ligand as cell death is efficiently induced in cells mutated or deficient for these factors limiting the risk of drug resistance development and maximizing its application spectrum. The simultaneous modulation of multiple (epigenetic) targets promises to open new avenues with unanticipated potential against cancer. Mol Cancer Ther; 10(12); 2394–404. ©2011 AACR.


Journal of Medicinal Chemistry | 2014

1,3,4-Oxadiazole-containing histone deacetylase inhibitors: Anticancer activities in cancer cells

Sergio Valente; Daniela Trisciuoglio; Teresa De Luca; Angela Nebbioso; Donatella Labella; Alessia Lenoci; Chiara Bigogno; Giulio Dondio; Marco Miceli; Gerald Brosch; Donatella Del Bufalo; Lucia Altucci; Antonello Mai

We describe 1,3,4-oxadiazole-containing hydroxamates (2) and 2-aminoanilides (3) as histone deacetylase inhibitors. Among them, 2t, 2x, and 3i were the most potent and selective against HDAC1. In U937 leukemia cells, 2t was more potent than SAHA in inducing apoptosis, and 3i displayed cell differentiation with a potency similar to MS-275. In several acute myeloid leukemia (AML) cell lines, as well as in U937 cells in combination with doxorubicin, 3i showed higher antiproliferative effects than SAHA.


The International Journal of Biochemistry & Cell Biology | 2009

TNF-related apoptosis-inducing ligand: Signalling of a ‘smart’ molecule

Fabio Manzo; Angela Nebbioso; Marco Miceli; Mariarosaria Conte; Floriana De Bellis; Vincenzo Carafa; Gianluigi Franci; Francesco Paolo Tambaro; Lucia Altucci

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor super-family and signals via two death receptors, TRAIL-R1 and TRAIL-R2, and two decoy receptors, TRAIL-R3 and TRAIL-R4, differently expressed in normal and cancer cells. TRAIL is mainly studied for its capacity to induce apoptosis preferentially in cancer cells. TRAIL is expressed in a variety of human tissues, in particular in the lymphoid system, suggesting a strong physiological role in the innate immunity. This review will focus on TRAIL gene structure and regulation, protein folding, tissue expression and molecular signalling. Finally, the potential use of TRAIL as anticancer treatment alone or in combination therapy as well as the use of drugs which signal via TRAIL and its receptors will be analyzed.


Cell Proliferation | 2012

Psidium guajava L. anti-neoplastic effects: induction of apoptosis and cell differentiation

Paola Bontempo; Antonella Doto; Marco Miceli; Luigi Mita; Rosaria Benedetti; Angela Nebbioso; M. Veglione; Daniela Rigano; Michele Cioffi; Vincenzo Sica; Anna Maria Molinari; Lucia Altucci

Objectives:  Curative properties of medicinal plants such as Psidium guajava L. (Myrtaceae) have often been indicated by epidemiological studies on populations in which these fruits are consumed daily. However, complete characterization of the active principles responsible for this ability has never been performed. Here, we have characterized P. guajava’s anti‐cancer potential and identified the parts of the fruit involved in its anti‐neoplastic action.


ChemMedChem | 2010

New Anacardic Acid-Inspired Benzamides: Histone Lysine Acetyltransferase Activators

José A. Souto; Rosaria Benedetti; Katharina Otto; Marco Miceli; Rosana Alvarez; Lucia Altucci; Angel R. de Lera

A series of N‐(4‐cyano‐3‐trifluoromethyl‐phenyl)‐2‐ethoxy‐6‐alkyl (and alkenyl) benzamides related to the anacardic acid derivative CTPB have been prepared from 2,6‐dihydroxybenzoic acid with a Suzuki coupling and addition of the anion of 4‐cyano‐3‐trifluoromethylphenylamine to a benzodioxinone as the key steps. In U937 cells, these analogues, in particular 7 c, 7 d, 7 f and 7 j, induced cell‐cycle arrest in the G1 phase, caused apoptosis in about 20 % of the cells, and increased the acetylation levels of H3. These activities correlate with the enzymatic activation of histone lysine acetyltransferases (KATs): CBP and PCAF.


Journal of Translational Medicine | 2009

Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells

Paola Bontempo; Luigi Mita; Antonella Doto; Marco Miceli; Angela Nebbioso; Ilaria Lepore; Gianluigi Franci; Roberta Menafra; Vincenzo Carafa; Mariarosaria Conte; Floriana De Bellis; Fabio Manzo; Vincenzo Di Cerbo; Rosaria Benedetti; Loredana D'Amato; Maria Marino; Alessandro Bolli; Giovanna Del Pozzo; Nadia Diano; Marianna Portaccio; Gustavo D Mita; Maria Teresa Vietri; Michele Cioffi; Ernesto Nola; Carmela Dell'Aversana; Vincenzo Sica; Anna Maria Molinari; Lucia Altucci

Background:BPA (bisphenol A or 2,2-bis(4-hydroxy-phenol)propane) is present in the manufacture of polycarbonate plastic and epoxy resins, which can be used in impact-resistant safety equipment and baby bottles, as protective coatings inside metal food containers, and as composites and sealants in dentistry. Recently, attention has focused on the estrogen-like and carcinogenic adverse effects of BPA. Thus, it is necessary to investigate the cytotoxicity and apoptosis-inducing activity of this compound.Methods:Cell cycle, apoptosis and differentiation analyses; western blots.Results:BPA is able to induce cell cycle arrest and apoptosis in three different acute myeloid leukemias. Although some granulocytic differentiation concomitantly occurred in NB4 cells upon BPA treatment, the major action was the induction of apoptosis. BPA mediated apoptosis was caspase dependent and occurred by activation of extrinsic and intrinsic cell death pathways modulating both FAS and TRAIL and by inducing BAD phosphorylation in NB4 cells. Finally, also non genomic actions such as the early decrease of both ERK and AKT phosphorylation were induced by BPA thus indicating that a complex intersection of regulations occur for the apoptotic action of BPA.Conclusion:BPA is able to induce apoptosis in leukemia cells via caspase activation and involvement of both intrinsic and extrinsic pathways of apoptosis.


Journal of Medical Genetics | 2013

Paternal deletion of the 11p15.5 centromeric-imprinting control region is associated with alteration of imprinted gene expression and recurrent severe intrauterine growth restriction

Agostina De Crescenzo; Angela Sparago; Flavia Cerrato; Orazio Palumbo; Massimo Carella; Marco Miceli; Moshe Bronshtein; Andrea Riccio; Yuval Yaron

Background Heterogeneous molecular defects affecting the 11p15.5 imprinted gene cluster are associated with the opposite growth disorders Beckwith-Wiedemann Syndrome (BWS) and Silver Russell syndrome (SRS). Maternal deletions of the centromeric domain usually result in BWS, but paternal deletions have been so far associated with normal phenotype. Here we describe a case of recurrent severe Intra-Uterine Growth Restriction (IUGR) with paternal transmission of an 11p15.5 60 kb deletion. Methods and results Chromosome microarray (CMA), PCR and DNA sequencing analyses showed that two fetuses conceived by a normal couple inherited from their father a 60 kb deletion encompassing the Imprinting Control Region of the 11p15.5 centromeric domain. The two fetuses died in utero with severe growth restriction. PCR amplification of parental DNAs indicated that the father carried the mutation in the mosaic state. DNA methylation and gene expression analyses showed that the deletion led to an imprinting alteration restricted to the centromeric domain and resulting in silencing of KCNQ1OT1 and activation of CDKN1C and PHLDA2. Conclusions Our data demonstrate that the phenotype associated with 11p15.5 deletions is strongly influenced by the size of the region involved and indicate imprinting defects leading to CDKN1C and PHLDA2 activation as cause of severe IUGR.

Collaboration


Dive into the Marco Miceli's collaboration.

Top Co-Authors

Avatar

Lucia Altucci

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Angela Nebbioso

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Antonello Mai

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Dante Rotili

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Floriana De Bellis

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Gianluigi Franci

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Mariarosaria Conte

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Sergio Valente

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Vincenzo Carafa

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Gerald Brosch

Innsbruck Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge